1. Home
  2. QNCX vs CTMX Comparison

QNCX vs CTMX Comparison

Compare QNCX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNCX
  • CTMX
  • Stock Information
  • Founded
  • QNCX 2012
  • CTMX 2008
  • Country
  • QNCX United States
  • CTMX United States
  • Employees
  • QNCX N/A
  • CTMX N/A
  • Industry
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • CTMX Biotechnology: Pharmaceutical Preparations
  • Sector
  • QNCX Health Care
  • CTMX Health Care
  • Exchange
  • QNCX Nasdaq
  • CTMX Nasdaq
  • Market Cap
  • QNCX 47.7M
  • CTMX 444.3M
  • IPO Year
  • QNCX 2019
  • CTMX 2015
  • Fundamental
  • Price
  • QNCX $1.64
  • CTMX $2.41
  • Analyst Decision
  • QNCX Strong Buy
  • CTMX Strong Buy
  • Analyst Count
  • QNCX 5
  • CTMX 2
  • Target Price
  • QNCX $8.00
  • CTMX $5.00
  • AVG Volume (30 Days)
  • QNCX 353.3K
  • CTMX 2.6M
  • Earning Date
  • QNCX 08-12-2025
  • CTMX 08-07-2025
  • Dividend Yield
  • QNCX N/A
  • CTMX N/A
  • EPS Growth
  • QNCX N/A
  • CTMX 128.27
  • EPS
  • QNCX N/A
  • CTMX 0.49
  • Revenue
  • QNCX N/A
  • CTMX $147,557,000.00
  • Revenue This Year
  • QNCX N/A
  • CTMX N/A
  • Revenue Next Year
  • QNCX N/A
  • CTMX N/A
  • P/E Ratio
  • QNCX N/A
  • CTMX $5.15
  • Revenue Growth
  • QNCX N/A
  • CTMX 23.81
  • 52 Week Low
  • QNCX $0.51
  • CTMX $0.40
  • 52 Week High
  • QNCX $2.45
  • CTMX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • QNCX 64.95
  • CTMX 57.13
  • Support Level
  • QNCX $1.48
  • CTMX $2.15
  • Resistance Level
  • QNCX $1.68
  • CTMX $2.44
  • Average True Range (ATR)
  • QNCX 0.14
  • CTMX 0.22
  • MACD
  • QNCX 0.02
  • CTMX -0.03
  • Stochastic Oscillator
  • QNCX 85.71
  • CTMX 41.67

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: